Obesity trials recruiting in Alabama

All Obesity trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Anniston, Birmingham
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Guntersville
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Dothan
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Montgomery
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Pelham
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Alexander City, Birmingham, Fairhope, Mobile
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Cullman
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Tuscaloosa
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Cullman
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · Alabama: Birmingham, Mobile
• A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
  NCT06239116 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Dothan, Huntsville
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Anniston, Cullman
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Alabama: Birmingham
• A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
  NCT06760546 · Phase: Phase 3 · Ages: 4 Years and older · Sex: All (male and female) · Alabama: Birmingham
• AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
  NCT07503210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Anniston
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• CARBON: UAB Cardiovascular Research Biobank
  NCT05067231 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Alabama: Birmingham
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Mobile
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Cullman
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Anniston, Birmingham, Cullman
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Alabama: Pelham
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Alabama: Daphne, Fairhope, Huntsville, Mobile
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Alabama: Anniston, Daphne, Mobile
• FELLAShip to Better Health
  NCT07220213 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · Alabama: Birmingham
• GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
  NCT05216042 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Inspire HER: Inspiring the Heart and Emotions for Radical Health
  NCT06966258 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 79 Years · Sex: Female · Alabama: Birmingham
• Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
  NCT05124808 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 45 Years · Sex: Female · Alabama: Birmingham
• International Weight Control Registry
  NCT04907396 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Ketogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity
  NCT06736028 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Alabama: Birmingham, Dothan, Fairhope, Huntsville
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Dothan
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Dothan
• Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance
  NCT06785064 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
  NCT04971720 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
  NCT07770841 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Pelham
• Time-restricted Eating for Postpartum Weight Loss
  NCT06491537 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · Alabama: Birmingham